Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 18/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 18/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 18/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.44 |
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | TGM1 | P22735 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747845 | 0.96 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL8275268 | 0.84 | TPSAB1 (0.51) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL12153397 | 0.81 | TPSAB1 (0.49) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL16468337 | 0.79 | TPSAB1 (0.47) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL16467967 | 0.79 | HSD11B1 (0.48) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL18855837 | 0.78 | TPSAB1 (0.47) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL12991729 | 0.78 | HSD11B1 (0.52) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL13016393 | 0.78 | HSD11B1 (0.52) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL12791455 | 0.78 | HSD11B1 (0.47) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL1747773 | 0.78 | GPR119 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817036-B1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2012-07-04 | — | — | EP | claimed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | claimed |
| EP-1817036-B1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2012-07-04 | — | — | EP | disclosed |
| US-7863449-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-04 | — | — | US | disclosed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270653-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | TPSAB1 1048/4885TPSD1 1695/4885TPSG1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.